TiGenix

About TiGenix

TiGenix NV operated as an advanced biopharmaceutical company, established as a spin-off from the Katholieke Universiteit Leuven and Ghent University in 2000. The founders were Prof. Dr. Frank P. Luyten and Gil Beyen. Headquartered in Leuven, Belgium, with operations in Madrid, Spain, the firm focused on developing novel therapies for inflammatory and autoimmune diseases by utilizing the anti-inflammatory properties of stem cells.

The company's core business revolved around its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells (eASCs). This technology formed the basis of its product pipeline, aiming to provide treatments for conditions with high unmet medical needs. TiGenix's lead product candidate, Cx601 (darvadstrocel), was an injectable allogeneic stem cell therapy developed for the treatment of complex perianal fistulas, a severe and debilitating complication of Crohn's disease. This condition affects a significant number of Crohn's patients who have had an inadequate response to conventional or biologic therapies. Another product, ChondroCelect, was a cell-based therapy for cartilage repair in the knee and was noted as the first of its kind to receive approval in Europe.

The company's business model was rooted in extensive research and clinical development, funded through a combination of venture capital, debt instruments, and public market listings on Euronext Brussels and NASDAQ. A pivotal moment in its history was the partnership with Takeda Pharmaceutical Company. In July 2016, Takeda acquired the exclusive rights to commercialize and develop Cx601 outside of the United States. This collaboration evolved into a full acquisition, with Takeda announcing its intention to acquire TiGenix in January 2018 for approximately €520 million. The acquisition was completed in July 2018, after which TiGenix became a wholly-owned subsidiary of Takeda, and its shares were delisted from public exchanges.